- Global Pharma News & Resources

Eagle Genomics Selected for Catalonia-Based Initiative to Support Expansion into Spanish-Speaking Markets

Cambridge, UK – 27 January 2022 – Today, Eagle Genomics, the Deep Tech platform business pioneering the application of network science to biology across the Food and Nutrition, Biopharma, Beauty and Personal Care, and AgBio industries, announced that it has been selected to participate in the Fast-Track Programme to Barcelona-Catalonia Life Science Hub (‘Programme’), Catalonia Trade & Investment’s initiative for UK firms looking to expand to Spanish-speaking markets. 

As one of 10 UK biotech and life sciences companies in the scheme, Eagle Genomics will receive specialized support and connect with Barcelona-Catalonia’s vast life sciences expertise and talent pool. In the coming weeks, Eagle Genomics will also participate in the second part of the Programme, which will be a market access session led by Alira Health, local experts, and the UK’s Department of International Trade

Anthony Finbow, CEO, Eagle Genomics, said: “We’re pleased to be participating in the Fast-Track Programme to Barcelona-Catalonia Life Science Hub, as we continue to explore our potential in international growth markets including Spain and Latin America.

“By supporting research and development in critical areas like the microbiome with our AI-augmented knowledge discovery platform e[datascientist]™, we are supporting organizations to build a more generative, sustainable future for our food, water, soil, and human health. Working with the Catalonian region provides another exciting opportunity to fulfil our goal of becoming the world’s burgeoning global life sciences knowledge discovery hub.” 

Maria Elena Martyak, Head of Product Marketing, Eagle Genomics, commented: “Spain, and in particular Catalonia, represents an amazing opportunity for Eagle Genomics to continue to grow and develop multi-national partnerships and relationships. We are excited to progress to the Programme’s next stages.”  

The health expenditure of all Spanish-speaking markets is worth around USD $276B, with Spain being the second biggest investor in Latin America. Spain also ranks fourth worldwide in the number of its clinical trials, with half being conducted in Catalonia.  The Catalonia region also hosts 50% of all Spanish pharma and biotech activity.  

Marina Gonzalo, Scientific Marketing Manager, Eagle Genomics, said: “Eagle Genomics’ goal in this Programme is to help drive the ‘4th industrial (Bio) Revolution’ market shift in Catalonia.  To that end, we believe that e[datascientist]™ can empower the life sciences and biopharma industries to meet both current and future challenges, by helping drive the digital reinvention of science.” 

In October 2021, Eagle Genomics joined the inaugural Singaporean cohort for the UK Government’s Global Incubator Program – Gateway to Asia, a Singapore-focused internationalization assistance and accelerator program for UK-based companies. Prior to that, in March 2021, the company announced its new site and operations in India, in innovation hub Laxmi Cyber City, Hyderabad.

Editor Details

Related Links

Last Updated: 28-Jan-2022